Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Interventional × Muscle-invasive Bladder Cancer × Clear all

Phase

Status

Not yet recruiting 2 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 891 Neoplasms 759 Carcinoma, Non-Small-Cell Lung 741 Prostatic Neoplasms 477 Neoplasm Metastasis 445 Leukemia, Myeloid, Acute 444 Melanoma 399 Colorectal Neoplasms 389 Multiple Myeloma 386 Lung Neoplasms 366 Lymphoma 313 Pancreatic Neoplasms 311 Recurrence 307 Ovarian Neoplasms 303 Leukemia 296 Lymphoma, Non-Hodgkin 291 Leukemia, Lymphocytic, Chronic, B-Cell 268 Precursor Cell Lymphoblastic Leukemia-Lymphoma 245 Carcinoma, Renal Cell 230 Brain Neoplasms 224 Head and Neck Neoplasms 213 Myelodysplastic Syndromes 210 Carcinoma, Hepatocellular 210 Glioblastoma 207 Squamous Cell Carcinoma of Head and Neck 200 Lymphoma, Large B-Cell, Diffuse 199 Lymphoma, Follicular 195 Colonic Neoplasms 161 Stomach Neoplasms 158 Rectal Neoplasms 150

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡